Julie D. Burgess
Chief Accounting OfficerMs. Julie D. Burgess, CPA, serves as Chief Accounting Officer at Design Therapeutics, Inc. since September 13, 2021. She serves as Senior Vice President of Finance at Otonomy Inc. since May 2021 and served as its Vice President of Finance and Administration since January 2014 until May 2021. Ms. Burgess has experience in financial reporting, technical accounting, debt and equity financings, and financial planning and management for public and private companies. Prior to Otonomy, Ms. Burgess served as the Corporate Controller for Apricus Biosciences, Inc. from March 2012 to October 2013 and a consultant to several other biopharmaceutical companies including Cypress Biosciences, Inc. and Ocera Therapeutics, Inc. Previously, Ms. Burgess served as the Vice President of Finance and Operations for Phenomix Corporation, a privately held biotech company, held various financial management positions at General Instrument, and served as an auditor at KPMG, LLP. Ms. Burgess is a licensed CPA, has her M.S. degree in Business Administration from San Diego State University and a B.A. degree in Business Economics from University of California, Santa Barbara.
Positions
- Company NameDesign Therapeutics, Inc.Stock CodeDSGNPositionChief Accounting OfficerColleagues
- PSPratik ShahCo-Founder, President, CEO, Principal Financial Officer & Executive Chairperson
- SJSean JeffriesChief Operating Officer
- CMChris M. StorgardChief Medical Officer
- AZAseem Z. AnsariCo-Founder & Scientific Advisor
- JPJohn P. SchmidIndependent Director
- RWRodney W. LappeIndependent Director
- JDJustin D. GoverIndependent Director
